P1vital

Executive Summary

P1vital is a UK-based neuroscience and digital health company founded in 2002 that combines deep CNS science with digital technology to enhance clinical research. The company offers a validated eCOA platform and a suite of objective digital biomarkers, including its flagship Facial Expression Recognition Task (FERT), to improve data quality and sensitivity in clinical trials for CNS disorders. With over two decades of experience, P1vital has established itself as a key enabler for drug developers seeking more reliable and sensitive endpoints. The company's tools are designed to capture subtle changes in patient behavior and cognition, which can increase trial power and reduce sample sizes. As the pharmaceutical industry moves toward decentralized trials and digital endpoints, P1vital is well-positioned to capitalize on the growing demand for validated digital biomarkers. Its platform integrates seamlessly with existing eCOA systems, offering sponsors a way to enhance data collection without disrupting workflows. The company's expertise in neuropsychiatric indications like depression, schizophrenia, and Alzheimer's disease makes it a strategic partner for CNS-focused trials.

Upcoming Catalysts (preview)

• TBDFDA qualification of FERT as a drug development tool (DDT)40% success
• TBDMajor partnership with a top-20 pharmaceutical company for digital biomarker integration across multiple trials60% success
• Q1 2027Launch of a new digital biomarker for neurodegenerative diseases (e.g., Alzheimer's) expanding addressable market50% success